AbbVie, Inc. (ABBV)
264.49
-0.47
(-0.18%)
USD |
NYSE |
Aug 24, 16:00
264.58
+0.09
(+0.03%)
After-Hours: 20:00
AbbVie Price to Book Value
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| June 27, 2025 | 226.77 |
| June 26, 2025 | 232.34 |
| June 25, 2025 | 230.60 |
| June 24, 2025 | 230.80 |
| June 23, 2025 | 228.57 |
| June 20, 2025 | 230.49 |
| June 18, 2025 | 230.72 |
| June 17, 2025 | 230.71 |
| June 16, 2025 | 237.40 |
| June 13, 2025 | 237.68 |
| June 12, 2025 | 239.34 |
| June 11, 2025 | 238.20 |
| June 10, 2025 | 235.71 |
| June 09, 2025 | 235.29 |
| June 06, 2025 | 236.12 |
| June 05, 2025 | 233.19 |
| June 04, 2025 | 233.02 |
| June 03, 2025 | 232.91 |
| June 02, 2025 | 232.59 |
| May 30, 2025 | 231.49 |
| May 29, 2025 | 230.88 |
| May 28, 2025 | 227.74 |
| May 27, 2025 | 231.01 |
| May 23, 2025 | 227.95 |
| May 22, 2025 | 227.05 |
| Date | Value |
|---|---|
| May 21, 2025 | 226.13 |
| May 20, 2025 | 229.93 |
| May 19, 2025 | 231.00 |
| May 16, 2025 | 228.89 |
| May 15, 2025 | 225.98 |
| May 14, 2025 | 220.71 |
| May 13, 2025 | 233.85 |
| May 12, 2025 | 236.42 |
| May 09, 2025 | 229.62 |
| May 08, 2025 | 230.84 |
| May 07, 2025 | 233.96 |
| May 06, 2025 | 232.79 |
| May 05, 2025 | 243.88 |
| May 02, 2025 | 246.87 |
| May 01, 2025 | 240.49 |
| April 30, 2025 | 242.68 |
| April 29, 2025 | 240.70 |
| April 28, 2025 | 239.24 |
| April 25, 2025 | 231.43 |
| April 24, 2025 | 224.35 |
| April 23, 2025 | 220.23 |
| April 22, 2025 | 216.16 |
| April 21, 2025 | 211.66 |
| April 17, 2025 | 215.18 |
| April 16, 2025 | 213.55 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Biogen, Inc. | 1.709 |
| Gilead Sciences, Inc. | 15.40 |
| Regeneron Pharmaceuticals, Inc. | 2.702 |
| Amgen, Inc. | 20.53 |
| REGENXBIO, Inc. | 6.083 |
Price to Book Value Related Metrics
| PE Ratio | 74.78 |
| PS Ratio | 7.282 |
| PEG Ratio | 1.095 |
| Price to Free Cash Flow | 25.75 |
| Price | 264.49 |
| Earnings Yield | 1.34% |
| Market Cap | 467.37B |
| PEGY Ratio | 1.055 |
| Operating PE Ratio | 21.30 |
| Normalized PE Ratio | 32.85 |